Deltex Medical seeking to raise 2.5m pounds through share issue

AIM-listed Deltex Medical, the maker of a technological device which can monitor blood flow during and after operations, has announced a placing of more than 13m shares so as to raise 2.5m pounds.

AIM-listed Deltex Medical, the maker of a technological device which can monitor blood flow during and after operations, has announced a placing of more than 13m shares so as to raise 2.5m pounds.

The 13,157,895 new ordinary shares of one pence each are being placed by Arden Partners on behalf of Deltex at a price of 19p.

The proceeds of the placing are to be used to fund Deltex's second phase collaboration project with Premier Inc, a performance improvement alliance of more than 2,700 US hospitals and 90,000 other sites.

The programme aims to result in the implementation of CardioQ-ODM - its highly sensitive blood flow measuring device - in up to five US hospitals and will involve the payment of fees to Premier.

The programme will additionally give Deltex access to Premier's patient outcome and hospital cost data as well as Premier's clinical change management and quality improvement expertise.

The company estimated that the total additional costs of implementing CardioQ-ODM into three Premier alliance hospitals would be approximately £1.3m which would be spread over two years.

Nigel Keen, Chairman of Deltex Medical Group, commented: "This research collaboration is an exciting development for the company following on from the Duke University Medical Centre study where the CardioQ-ODM formed a core part of the enhanced recovery programme. We believe that Premier's alliance of 2,700 U.S hospitals could be the launch pad for a substantial increase in penetration of the US market by CardioQ-ODM".

NICE: £1,100 cost-saving per patient when device usedIn March 2011, the National Institute for Health and Clinical Excellence issued medical guidance on the device stating that the cost-saving per patient when Deltex' CardioQ-ODM was used instead of a central venous catheter in the peri-operative period was about £1,100 based on a 7.5-day hospital stay.

The guidance further stated: "There is a reduction in post-operative complications, use of central venous catheters and in-hospital stay compared with or without invasive cardiovascular monitoring."

MF

Recommended

Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021
Royal Mail will deliver for investors – here's how to play it
Trading

Royal Mail will deliver for investors – here's how to play it

Royal Mail Group has found its feet in the past 18 months and looks cheap. Matthew Partridge looks at how to trade the shares.
14 Sep 2021
The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Three hidden gems from Japan’s overlooked stockmarket
Share tips

Three hidden gems from Japan’s overlooked stockmarket

Professional investor Eiji Saito of JPMorgan’s Japan Small Cap Growth & Income fund picks three promising stocks from Japan's vibrant but under-resear…
13 Sep 2021

Most Popular

Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021
How you can profit from the power of the grey pound
Share tips

How you can profit from the power of the grey pound

Higher life expectancy and surging asset prices have proved a boon for the baby-boomer generation, which has accumulated vast wealth. Younger generati…
10 Sep 2021